Structure Therapeutics Inc.
No enriched coverage for $GPCR in the last 7 days.
No SEC Form 4 filings for $GPCR in the last 30 days.
See all $GPCR insider activity →Structure Therapeutics (GPCR) reported Phase 2 extension results for Aleniglipron, showing up to 16.2% mean weight loss at 72 weeks. CEO Ray Stevens highlighted safety, no drug-related liver injury, and lower manufacturing costs compared to Novo Nordisk and Lilly. According to Stocktwits.
Novo Nordisk (NVO) announced plans for larger acquisitions and over five multi-blockbuster launches by 2030, targeting $23B in pipeline sales by 2035. Shares of smaller obesity-focused companies Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Altimmune (ALT) rose, while NVO shares fell 8%. NVO's CagriSema treatment showed promising weight loss results, but investors remain cautious.
Structure Therapeutics (GPCR) reported a 3.3% weight-loss signal in a Phase 1/2a trial of ACCG-2671. The study involved 31 healthy adults, with six participants receiving 10mg showing the mean reduction. The company is now testing daily and weekly regimens in an 84-day study, with results expected in 2027. Investors focus on sustained efficacy and tolerability, as gastrointestinal side effects were reported at higher doses.
Recent GPCR coverage spans technology, corporate actions and financial news.
Positive Phase 2 results suggest strong efficacy and lower manufacturing costs, likely supporting a price uptick.
Strong efficacy data could position Structure as a key obesity play.
Early weight‑loss signal may boost investor optimism but tolerability concerns could limit upside.
Positive early‑stage trial results suggest significant upside potential for the company's weight‑loss pipeline.
New Phase 3 dosing milestone plus updated 2026 data timing and cash runway details can shift biotech risk pricing and near-term catalysts.
AlphAI scores every news story that mentions GPCR with an AI model for sentiment and relevance, and aggregates insider trades from Structure Therapeutics Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Structure Therapeutics (GPCR) reported Phase 2 extension results for Aleniglipron, showing up to 16.2% mean weight loss at 72 weeks. CEO Ray Stevens highlighted safety, no drug-related liver injury, and lower manufacturing costs compared to Novo Nordisk and Lilly. According to Stocktwits.
1 min readNovo Nordisk (NVO) announced plans for larger acquisitions and over five multi-blockbuster launches by 2030, targeting $23B in pipeline sales by 2035. Shares of smaller obesity-focused companies Viking Therapeutics (VKTX), Structure Therapeutics (GPCR), and Altimmune (ALT) rose, while NVO shares fell 8%. NVO's CagriSema treatment showed promising weight loss results, but investors remain cautious.
2 min readStructure Therapeutics (GPCR) reported a 3.3% weight-loss signal in a Phase 1/2a trial of ACCG-2671. The study involved 31 healthy adults, with six participants receiving 10mg showing the mean reduction. The company is now testing daily and weekly regimens in an 84-day study, with results expected in 2027. Investors focus on sustained efficacy and tolerability, as gastrointestinal side effects were reported at higher doses.
2 min readStructure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Structure Therapeutics Reports Positive Clinical Data Across Oral Small Molecule Amylin and GLP-1 Programs for Chronic Weight Management ACCG-2671 (oral small molecule amylin receptor agonist) demonstrated a ~6-day half-life, no serious adverse events, and evidence o
2 min readStructure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights First patients dosed in aleniglipron (oral small molecule GLP-1 receptor agonist) Phase 3 ACCOMPLISH program for chronic weight management Data from Phase 1 SAD clinical trial
6 min readCantor Fitzgerald analyst Prakhar Agrawal reiterated a Buy on Structure Therapeutics (NASDAQ:GPCR) on June 7 and set a $101 price target. BMO Capital analyst Evan Seigerman reiterated Buy on June 5 with a $145 target, citing clinical-trial results for aleniglipron showing sustained weight loss and a favorable safety profile, plus effects on blood pressure and inflammation.
4 min readThe article highlights three biotech takeover targets after AbbVie’s acquisition of Apogee Therapeutics, citing Big Pharma’s patent-cliff pressure and demand for de-risked assets. It names Revolution Medicines (Phase 3 RASolute 302: median OS 13.2 vs 6.7 months; shares ~$169.51; mkt cap ~$36B), Structure Therapeutics (oral GLP-1 aleniglipron Phase 2: ~16% weight loss; cash ~$1.5B; mkt cap ~$3.2B), and Legend Biotech (Carvykti revenue $1.03B FY2025; Q1 2026 $305.1M; shares $29.30; target $57.59).
7 min readStructure Therapeutics Inc. (GPCR) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. false 0001888886 True 0001888886 2026-06-17 2026-06-17 0001888886 gpcr:AmericanDepositarySharesAdssEachRepresentingThreeOrdinarySharesParValue0.0001PerOrdinaryShareMember 2026-06-17 2026-06-17 0001888886 gpcr:OrdinarySharesParValue0.0001PerShareMember 2026-06-17 2026-06-17 iso421
2 min readPolymarket traders and analysts are focusing on Viking Therapeutics (VKTX) as an obesity M&A target, citing an estimated 38.5% implied acquisition probability before 2027. The company has no revenue and a ~$3.59B market cap; shares closed at $30.89 on May 22, 2026. Analysts’ mean target is $92.33. Viking’s oral VK2735 showed up to 12.2% weight loss at 13 weeks, and Phase 3 VANQUISH-1 is fully enrolled with 4,500+ patients. Potential buyers mentioned include Eli Lilly, Pfizer, and Novo Nordisk.
7 min readWilliam Blair and Leerink Partners both maintained an "Outperform" rating on Structure Therapeutics (GPCR) on March 16, 2026, citing strong conviction in the company's oral GLP-1 program, aleniglipron. Despite modest intraday share declines, analysts emphasized the considerable market opportunity and clinical differentiation, without issuing new price targets. Investors are advised to view these ratings as affirmation of potential rather than immediate buy signals, awaiting further clinical readouts and commercialization details.
2 min read
